GnRH Analogues & Chemical Menopause for PMDD
Why we induce a chemical menopause, using GnRH analogues in PMDD treatment
Understanding how hormonal suppression can help manage severe PMDD
Premenstrual Dysphoric Disorder (PMDD) is a severe hormone-sensitive condition that can significantly affect emotional wellbeing, relationships and everyday life. Symptoms commonly include anxiety, irritability, low mood, emotional sensitivity and difficulty coping, particularly in the weeks before menstruation.
For some women, treatments such as antidepressants, psychological therapies or hormonal contraception do not provide sufficient relief. In these circumstances, GnRH analogues, combined with hormone replacement therapy (HRT), can offer an effective alternative.
This treatment works by temporarily switching off the menstrual cycle and reducing the hormonal fluctuations that trigger PMDD symptoms.
Why do GnRH analogues help PMDD?
PMDD is not usually caused by having too much or too little oestrogen or progesterone. Instead, research suggests that women with PMDD are particularly sensitive to the normal changes in hormone levels throughout the menstrual cycle.
These hormonal fluctuations can affect brain chemicals involved in mood regulation, including serotonin and GABA, contributing to the emotional and psychological symptoms of PMDD.
GnRH analogues temporarily suppress the ovaries, preventing ovulation and significantly reducing the normal monthly fluctuations in oestrogen and progesterone. This creates a temporary, reversible menopause.
By removing the hormonal changes that trigger PMDD, many women experience a substantial improvement in their symptoms. Research suggests that approximately 60–75% of women with severe premenstrual disorders respond to GnRH analogue treatment, although individual responses vary.
Why is HRT needed alongside GnRH analogues?
Although suppressing ovarian hormones can be very effective for PMDD, oestrogen is essential for maintaining bone health and general wellbeing. Without oestrogen, women may experience hot flushes, night sweats, poor sleep and vaginal dryness. Longer-term oestrogen deficiency can also lead to bone loss.
HRT is therefore often introduced alongside GnRH analogue treatment. This is known as HRT add-back therapy. The aim is to replace enough oestrogen to protect health and ease menopausal symptoms while continuing to suppress the natural hormonal cycle.
Women who have a uterus also need a form of progesterone or progestogen to protect the womb lining. Some women with PMDD are particularly sensitive to these hormones, so finding the right HRT combination can require careful adjustment.
Research suggests that it is often the change in hormone levels, rather than stable hormone levels themselves, that triggers PMDD symptoms. Maintaining consistent hormone levels is therefore an important aim of treatment.
Nasal sprays or injections: which is better?
GnRH analogues can be given as a nasal spray or as a longer-acting injection. Both work in a similar way, but there are practical differences.
Nasal sprays
Nasal preparations, such as nafarelin, are taken regularly and offer greater flexibility when starting treatment. They can be stopped more readily if side effects occur or treatment is not well tolerated.
For this reason, a nasal spray may be a useful option for an initial trial, allowing women to assess their response before considering longer-acting treatment. However, it must be used consistently to maintain effective hormone suppression.
Injections
Longer-acting preparations, such as goserelin, generally provide hormone suppression for several weeks. They can be convenient because they avoid daily treatment, but their effects cannot be immediately reversed once administered.
Neither approach has been proven more effective than the other specifically for PMDD. The choice depends on individual circumstances, preferences and specialist advice.
How effective is GnRH Chemical Menopause treatment for PMDD?
GnRH analogues are a recognised option for severe PMDD, particularly when other treatments have been unsuccessful. Studies have shown meaningful improvement in symptoms and quality of life for many women, including:
· Anxiety, irritability and low mood
· Emotional sensitivity and mood swings
· Feeling overwhelmed or unable to cope
· Physical premenstrual symptoms
· Relationships and everyday functioning
Is GnRH treatment recommended for PMDD in the UK?
Yes. The Royal College of Obstetricians and Gynaecologists (RCOG) recognises GnRH analogues as a specialist option for severe premenstrual disorders, particularly when other treatments have not been effective. RCOG guidance also recommends HRT add-back during longer-term treatment to help protect bone health.
The National Association for Premenstrual Syndromes (NAPS) also includes GnRH analogues with HRT add-back in its treatment guidance. Their use specifically for PMDD is generally off-label in the UK and requires specialist assessment and monitoring.
Could GnRH treatment be right for you?
For women living with severe PMDD, especially when other treatments have provided limited relief, GnRH analogues can offer another option. By temporarily switching off the menstrual cycle and using carefully chosen HRT to maintain hormone levels, treatment aims to reduce the hormonal fluctuations responsible for symptoms.
Although not suitable for everyone, this combination can significantly improve symptoms and quality of life for some women. A specialist consultation can help assess whether the approach is appropriate and explain its benefits, limitations and monitoring.
References and further reading
1. Royal College of Obstetricians and Gynaecologists. Management of Premenstrual Syndrome. Green-top Guideline No. 48. BJOG. 2017. Read online
2. RCOG. Managing Premenstrual Syndrome (PMS): patient information. Read online
3. National Association for Premenstrual Syndromes (NAPS). Treatment information. Read online
4. Schmidt PJ et al. Differential behavioral effects of gonadal steroids. New England Journal of Medicine. 1998. Read online
5. Schmidt PJ et al. PMDD symptoms following ovarian suppression: triggered by change in ovarian steroid levels. American Journal of Psychiatry. 2017. Read online
6. Nevatte T et al. ISPMD consensus on the management of premenstrual disorders. Archives of Women’s Mental Health. 2013. Read online
